Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zai Lab Ltd ( (HK:9688) ) has shared an announcement.
Zai Lab reported first-quarter 2026 revenues of $99.6 million, reflecting expected seasonal dynamics and competitive pressure on key drugs ZEJULA and VYVGART, while underscoring that its commercially profitable regional business continues to provide a stable base. Management highlighted preparations for the China launch of KarXT for schizophrenia in the second quarter and ongoing regulatory review of TIVDAK, alongside positive Phase 3 data for povetacicept in IgA nephropathy and elegrobart in thyroid eye disease as key drivers of future regional growth.
The company emphasized strong momentum in its global R&D pipeline, with standout clinical data for its oncology asset zoci in small cell lung cancer and extrapulmonary neuroendocrine carcinomas and rapid enrollment in the registrational DLLEVATE trial, as well as new collaborations with Amgen and Boehringer Ingelheim that could position zoci as a backbone therapy in neuroendocrine tumors. In immunology, ZL-1503 showed promising preclinical dual-pathway activity across atopic diseases, supporting a Phase 1/1b study now underway, reinforcing Zai Lab’s strategy to scale its research engine and enhance its competitive positioning in both oncology and immunology.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, immunology and other serious diseases, with operations spanning China and global markets. Its portfolio includes marketed products such as ZEJULA and VYVGART in its regional business, alongside a growing global pipeline that features assets like zocilurtatug pelitecan (zoci), ZL-1503 and upcoming launches including KarXT and potential approvals for TIVDAK, povetacicept and elegrobart.
Average Trading Volume: 10,778,890
Technical Sentiment Signal: Sell
Current Market Cap: HK$18.31B
For detailed information about 9688 stock, go to TipRanks’ Stock Analysis page.